

HHS Public Access

Author manuscript *Org Lett.* Author manuscript; available in PMC 2019 January 05.

Published in final edited form as:

Org Lett. 2018 January 05; 20(1): 96–99. doi:10.1021/acs.orglett.7b03456.

Enantioselective Synthesis of Spliceostatin G and Evaluation of Bioactivity of Spliceostatin G and its Methyl ester

Arun K. Ghosh^{*,†}, Guddeti Chandrashekar Reddy[†], Andrew J. MacRae[‡], and Melissa S. Jurica[‡]

[†]Department of Chemistry and Department of Medicinal Chemistry, Purdue University, 560 Oval Drive, West Lafayette, Indiana 47907

[‡]Department of Molecular Cell and Developmental Biology and Center for Molecular Biology of RNA, University of California, Santa Cruz, California 95064

Abstract

An enantioselective total synthesis of spliceostatin G has been accomplished. The synthesis involved a Suzuki cross-coupling reaction as the key step to construct spliceostatin G. The functionalized tetrahydropyran ring was constructed from commercially available optically active tri-*O*-acetyl-D-glucal. Other key reactions include highly stereoselective Claisen rearrangement, 1,4 addition of MeLi to install C8 methyl group and reductive amination to incorporate the C10 amine functionality of spliceostatin G. Our biological evaluation of synthetic spliceostatin G and its methyl ester revealed that it does not inhibit splicing in vitro.

Graphical abstract



In mammalian cells, the splicing of pre-mRNAs is a fundamental process for gene expression.^{1,2} Splicing is carried out by a complex ribonuclear machinery, called spliceosome which upon recognition of splicing signal, catalyzes the removal of non-coding sequences (introns) and assembles protein coding sequences (exons) to form messenger mRNA prior to export and translation.^{3,4} These transcription and translation steps are generally very complicated. Recent studies have revealed that splicing is pathologically altered in many different ways in cancer cells.^{5,6} Therefore, manipulation or inhibition of splicing events by targeting spliceosome may be an effective strategy for anticancer drug development. Among strategies modulation of spliceosome to target cancer therapeutically

^{*}Corresponding Authors: akghosh@purdue.edu.

Supporting Information

Supporting Information Available General experimental procedures, characterization data for all new products. This material is available free of charge via the Internet at http://pubs.acs.org.

has become an area of significant interest. Pladienolides (pladienolide B, 1, Figure 1) isolated from *Streptomyces*, were shown to be potently cytotoxic.^{7,8} They inhibit spliceosome by binding to SF3B subunit of spliceosome.^{9,10} While pladienolides are unsuitable for clinical use, a semisynthetic derivative E707, 2 underwent clinical trials.^{11,12} Subsequently, other natural products, such as FR901464, 3, and its methylated derivative spliceostatin A, 4 were shown to potently inhibit spliceosome through binding to SF3B subunit of spliceosome.^{13,14} Total synthesis and further design of structural isomers were pursued for these natural products to improve stability and reduce structural complexities of these agents. Recently,^{15,16,17} He and co-workers reported isolation and structural studies of a series of spliceostatin class of natural products from the fermentation broth FERM BP-3421 of *Burkholderia* sp.¹⁸ Among these natural products, a less complex structure, spliceostatin G was isolated and full structure of spliceostatin G was confirmed by detailed ¹H- and ¹³C-NMR studies.¹⁸ Spliceostatin G did not exhibit potent cytotoxicity inherent to other spliceostatins. Spliceostatin G does not contain epoxy alcohol on a tetrahydropyran framework or 5,6-dihydro-a-pyrone subunit present in more active natural products like spliceostating A and E.¹⁸ As part of continuing interests in the chemistry and biology of spliceostatins, we have devised an enantioselective synthesis of spliceostatin G using readily available tri-O-acetyl-D-glucal as the key starting material. Current synthesis will provide ready access to highly functionalized tetrahydropyran and the diene frameworks of spliceostatins.

Our strategy for an enantioselective synthesis of spliceostatin G is shown in Scheme 1. To construct the diene component of spliceostatin G we planned a Suzuki cross-coupling reaction between the boronate segment **7** and iodoacrylate **6** at a late stage of the synthesis. The boronate derivative **7** would be obtained by a cross-metathesis reaction of amide derivatives of olefin **8** and commercially available pinacol boronate. Coupling of amine-functionality of **8** with acid **9** would provide the requisite amide for cross-metathesis. The functionalized tetrahydropyran ring **8** could be constructed from dihydropyran derivative **10**. Optically active synthesis of this dihydropyran derivative would be carried out from commercially available tri-*O*-acetyl-D-glucal **11**.

The synthesis of dihydropyran derivative **12** was carried out in multigram scale from commercially available tri-*O*-acetyl-D-glucal **11** as reported in the literature.¹⁹ This was subjected to heating in a sealed tube in toluene at 190 °C for 18 h to provide the Claisen rearrangement product, the corresponding aldehyde. Wittig olefination of the aldehyde with methylene-triphenylphosphorane at 0 °C afforded dihydropyran derivative **13** in 90% yield. The removal of the silyl group was carried out by exposure to *n*Bu₄N⁺F⁻ (TBAF) in THF at 0 °C to 23 °C for 12 h. The resulting alcohol was initially treated with *p*-toluenesulfonyl chloride in pyridine at 23 °C for 12 h to furnish a mixture (6 : 1) of tosylate derivatives **14** and **15**. For regioselective formation of primary sulfonate derivative, we chose a sterically bulkier 2,4,6-triisopropylbenzenesulfonyl chloride (TPSCI). Reaction of diol with TPSCl in pyridine at 0 °C to 23 °C for 24 h afforded primary sulfonate derivative **16** in 92% yield. Reduction of sulfonate **16** by LAH in THF at 0 °C to 65 °C for 1 h provided the reduction product, the methyl derivative. Oxidation of the resulting allylic alcohol with Dess-Martin periodinane at 0 °C to 23 °C for 1.5 h furnished enone derivative **17** in 80% yield. For

Org Lett. Author manuscript; available in PMC 2019 January 05.

stereoselective installation of C5-methyl group, we carried out a 1,4-addition as developed by us previously.¹⁷ Thus, treatment of **17** with MeLi in the presence of CuBr•Me₂S complex at -78 °C for 2 h provided dihydro-2*H*-pyranone **18** in excellent yield and excellent diastereoselectivity (25:1 by ¹H-NMR and ¹³C-NMR analysis).

Elaboration of dihydropyranone **18** to boronate derivative **7** is shown in Scheme 3. A substrate control stereoselective reduction of ketone **18** with ammonium acetate and NaBH(OAc)₃ in the presence of trifluoroacetic acid (TFA) at 23 °C for 12 h afforded primary amine **8** with high diastereoselectivity (96:4 by ¹H-NMR analysis).^{17,20} Coupling of optically active acid **9** and amine **8** using HATU in the presence of diisopropylethylamine (DIPEA) resulted in amide derivative **19** in 85% yield. Cross-metathesis of allyl derivative **19** with commercially available pinacol boronate **20** in the presence of Grubb's 2nd generation catalyst (10%) in 1,2-dichloroethane at 80 °C for 1 h afforded boronate derivative **7** in 41% yield.^{21,22,23}

The synthesis of spliceostatin G is shown in Scheme 4. Initially, we conducted Suzuki coupling of boronate **7** and iodocarboxylic acid **6a** using Pd(dppf)Cl₂•DCM catalyst (20 mol %) in the presence of aqueous K₃PO₄ in a mixture of dioxane and acetonitrile at 23 °C for 30 min. However, this condition only provided trace amount of coupling product spliceostatin G. We have also carried out this coupling using Pd(Ph₃P)₄ catalyst (10 mol%) in the presence of Cs₂CO₃ at 55 °C. This condition only provided trace amount of desired product.²⁴ We then carried out this Suzuki reaction²⁵ with methyl iodoacrylate **6b** using Pd(dppf)₂Cl₂•DCM (20 mol%) catalyst in the presence of aqueous K₃PO₄ at 23 °C for 30 min to furnish coupling product **21** in 75% yield after silica gel chromatography. The methyl ester **21** was converted to spliceostatin G by saponification with aqueous LiOH in THF at 23 °C for 6 h, followed by reaction of the resulting hydroxyl acid with acetyl chloride in CH₂Cl₂ at 23 °C for 3 h. Spliceostatin G was obtained in 68% yield over two-steps. The ¹H-NMR and ¹³C-NMR of our synthetic spliceostatin G {[a]_D²³–71.7 (*c* 0.53, CHCl₃)²⁶ are in full agreement with the reported spectra of natural spliceostatin G.¹⁸

The biological properties of synthetic spliceostatin G (**5**) and the precursor **21** were evaluated in an *in vitro* splicing system as previously described.²⁷ (Figure 2). Neither compound showed inhibition of splicing in this system, even at 100 μ M concentration. In contrast, spliceostatin A in the same assay shows strong splicing inhibition. This result is consistent with previous reports showing that spliceostatin G (**5**) does not affect the growth of several cancer cell lines.¹⁸

In summary, we have achieved an enantioselective synthesis of spliceostatin G and confirmed the assignment of relative and absolute stereochemistry of spliceostatin G. The synthesis involved a Suzuki cross-coupling reaction as the key step. Enantioselective synthesis of the functionalized tetrahydropyran ring was achieved from commercially available optically active tri-*O*-acetyl-D-glucal using a highly stereoselective Claisen rearrangement.

A cross-metathesis of commercially available pinacol boronate using Grubbs' catalyst provided the vinyl boronate derivative for the cross coupling reaction with iodoacrylic acid.

Org Lett. Author manuscript; available in PMC 2019 January 05.

The other stereoselective transformations include highly stereoselective 1,4 addition to construct C8 methyl group and reductive amination to incorporate the C10 amine functionality of spliceostatin G. The synthesis is convergent and amenable to the synthesis of structural variants. We have also evaluated spliceosome inhibitory activity of spliceostatin G and compared its activity with spliceostatin A. Spliceostatin G does not inhibit *in vitro* splicing assembly or chemistry. The design and synthesis of structural variants of spliceostatins are in progress. These analogs will be important to clarify the link between splicing inhibition and changes in cellular function induced by these remarkable compounds.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support by the National Institutes of Health and Purdue University is gratefully acknowledged. We thank Dr. Margherita Brindisi (Purdue University) for helpful discussions.

References

- 1. Wahl MC, Will CL, Lührmann R. Cell. 2009; 136:701–718. [PubMed: 19239890]
- 2. Roybal GA, Jurica MS. Nucleic Acids Res. 2010; 38:6664-6672. [PubMed: 20529876]
- 3. Will CL, Luhrmann R. Cold Spring Harb Perspect Biol. 2011:3.
- 4. Rymond B. Nat Chem Biol. 2007; 3:533–535. [PubMed: 17710096]
- 5. Van Alphen RJ, Wiemer EA, Burger H, Eskens FA. Br J Cancer. 2009; 100:228–232. [PubMed: 19034274]
- 6. Cooper TA, Wan L, Dreyfuss G. Cell. 2009; 136:777-793. [PubMed: 19239895]
- Sakai T, Sameshima T, Matsufuji M, Kawamura N, Dobashi K, Mizui Y. J Antibiot. 2004; 57:173– 179. [PubMed: 15152802]
- Sakai T, Asai N, Okuda A, Kawamura N, Mizui Y. J Antibiot. 2004; 57:180–187. [PubMed: 15152803]
- 9. Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M, Ishihama Y, Iwata M, Mizui Y. Nat Chem Biol. 2007; 3:570–575. [PubMed: 17643112]
- Yokoi A, Kotake Y, Takahashi K, Kadowaki T, Matsumoto Y, Minoshima Y, Sugi NH, Sagane K, Hamaguchi M, Iwata M, Mizui Y. FEBS J. 2011; 278:4870–4880. [PubMed: 21981285]
- Sato M, Muguruma N, Nakagawa T, Okamoto K, Kimura T, Kitamura S, Yano H, Sannomiya K, Goji T, Miyamoto H, Okahisa T, Mikasa H, Wada S, Iwata M, Takayama T. Cancer Sci. 2014; 105:110–116. [PubMed: 24635824]
- Butler, MA. Natural Product-Derived Compounds in Late State Clinical Development at the End of 2008. Buss, A., Butler, M., editors. The Royal Chemical Society of Chemistry; Cambridge, UK: 2009. p. 321-354.
- Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami K, Watanabe H, Kitahara T, Yoshida T, Nakajima H, Tani T, Horinouchi S, Yoshida M. Nat Chem Biol. 2007; 3:576–583. [PubMed: 17643111]
- 14. Nakajima H, Hori Y, Terano H, Okuhara M, Manda T, Matsumoto S, Shimomura K. Antibiot. 1996; 49:1204–1211.
- (a) Thompson CF, Jamison TF, Jacobsen EN. J Am Chem Soc. 2000; 122:10482–10483.(b) Thompson CF, Jamison TF, Jacobsen EN. J Am Chem Soc. 2001; 123:9974–9983. [PubMed: 11592876] (c) Horigome M, Motoyoshi H, Watanabe H, Kitahara T. Tetrahedron Lett. 2001; 42:8207–8210.(d) Motoyoshi H, Horigome M, Watanabe H, Kitahara T. Tetrahedron. 2006; 62:1378–1389.

- (a) Albert BJ, Koide K. Org Lett. 2004; 6:3655–3658. [PubMed: 15469316] (b) Albert BJ, Sivaramakrishnan A, Naka T, Koide K. J Am Chem Soc. 2006; 128:2792–2793. [PubMed: 16506745] (c) Albert BJ, Sivaramakrishnan A, Naka T, Czaicki NL, Koide K. J Am Chem Soc. 2007; 129:2648–2659. [PubMed: 17279752]
- 17. (a) Ghosh AK, Chen ZH. Org Lett. 2013; 15:5088–5091. [PubMed: 24050251] (b) Ghosh AK, Chen ZH, Effenberger KA, Jurica MS. J Org Chem. 2014; 79:5697–5709. [PubMed: 24873648]
- He H, Ratnayake AS, Janso JE, He M, Yang HY, Loganzo F, Shor B, O'Donnell CJ, Koehn FE. J Nat Prod. 2014; 77:1864–1870. [PubMed: 25098528]
- (a) Pazos G, Pérez M, Gándara Gómez G, Fall Y. Tetrahedron Lett. 2009; 50:5285–5287.(b) Hoberg JO. Carbohydr Res. 1997; 300:365–367.(c) Mori Y, Hayashi H. J Org Chem. 2001; 66:8666–8668. [PubMed: 11735556]
- Abdel-Magid AF, Carson KG, Harris BD, Maryanoff CA, Shah RD. J Org Chem. 1996; 61:3849– 3862. [PubMed: 11667239]
- 21. Scholl M, Ding S, Lee CW, Grubbs RH. Org Lett. 1999; 1:953–956. [PubMed: 10823227]
- 22. Trnka TM, Morgan JP, Sanford MS, Wilhelm TE, Scholl M, Choi T-L, Ding S, Day MW, Grubbs RH. J Am Chem Soc. 2003; 125:2546–2558. [PubMed: 12603143]
- Nicolaou KC, Rhoades D, Lamani M, Pattanayak MR, Kumar SPM. J Am Chem Soc. 2016; 138:7532–7535. [PubMed: 27266914]
- 24. Suzuki A. J Organomet Chem. 1999; 576:147-168.
- 25. Biajoli AFP, Schwalm CS, Limberger J, Claudino TS, Monteiro AL. J Braz Chem Soc. 2014; 25:2186–2214.
- 26. Optical rotation of natural spliceostatin G has not been reported (see reference¹⁸)
- Effenberger KA, Anderson DD, Bray WM, Prichard BE, Ma N, Adams MS, Ghosh AK, Jurica MS. J Biol Chem. 2014; 289:1938–1947. [PubMed: 24302718]







Figure 2.

Impact of spliceostatin G on *in vitro* splicing. Average splicing efficiency relative to inhibitor concentration normalized to DMSO control. SSG, spliceostatin G; compound **21**; SSA, spliceostatin A.



Scheme 1. Retrosynthesis of Spliceostatin G



Scheme 2. Synthesis of dihydropyranone 18



Scheme 3. Synthesis of boronate derivative 7



Scheme 4. The synthesis of spliceostatin G.